Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06429150 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jul 11, 2027 → Dec 31, 2027
See other at-risk trials from Shenzhen Geno-Immune Medical Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: May 11, 2024 to Dec 31, 2026v5 Show 5 more changesShow less
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Primary completion pushed from Jul 11, 2027 to Dec 31, 2027
    • Study completion pushed from Dec 31, 2027 to Dec 31, 2028
    • Study description expanded, about 66 words
    • Site details revised
  2. Study sites: 2 to 1
    • Collaborators shortened, about 9 words
    v4
  3. 2 versions Re-verified since Jun 7, 2024, no change to tracked fieldsv2-v3
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Trial Details
NCT Number NCT06429150
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Multiple Myeloma, Plasmacytoma
Related terms Multiple Myeloma, Plasmacytoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov